Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances

doi:10.5306/wjco.v13.i6.448

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4032)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

295

WORD

HTML

2475

Figures (1-2)

201

Tables (1-4)

162

Sum=3203

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

300

Download

529

Sum=829

Jun 24, 2022 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jun 24, 2022; 13(6): 448-472
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448

Table 1 Ongoing clinical trials investigating immune checkpoint inhibitor - oral tyrosine kinase inhibitor combinations

NCT	Phase	Study drugs	Treatment line	Endpoint	Estimated End of Trial
NCT04194775	3	CS1003 +LENVATINIB vs LENVATINIB	1	OS, PFS	June 2023
NCT04344158	3	PENPULIMAB + ANLOTINIB vs SORAFENIB	1	OS	December 2024
NCT03713593	3	PEMBROLIZUMAB + LENVATINIB vs LENVATINIB	1	OS, PFS	May 2022
NCT04411706	2	SINTILIMAB + APATINIB + CAPECITABINE	1	ORR	June 2022
NCT04042805	2	SINTILIMAB + LENVATINIB	1	ORR	August 2024
NCT04444167	2	BISPECIFIC AK104 + LENVATINIB	1	ORR	March 2022
NCT04183088	2	TISLELIZUMAB + REGORAFENIB	1	ORR, PFS, Safety	March 2025
NCT04310709	2	NIVOLUMAB + REGORAFENIB	1	ORR	May 2023
NCT04442581	2	PEMBROLIZUMAB + CABOZANTINIB	1	ORR	September 2024
NCT03439891	2	NIVOLUMAB + SORAFENIB	1	MTD, ORR	May 2022
NCT04170556	2	NIVOLUMAB + REGORAFENIB	2	Safety	December 2022
NCT04401800	1b/2	TISLELIZUMAB + LENVATINIB	1	ORR	December 2022
NCT04443309	1b/2	CAMRELIZUMAB + LENVATINIB	1	ORR	August 2024
NCT03347292	1	PEMBROLIZUMAB + REGORAFENIB	1	DLT, Safety	October 2022

NCT: Number of the clinical trial (Clinicaltrials.gov); OS: Overall survival; PFS: Progression-free survival; ORR: Overall response rate; MTD: Maximum tolerated dose; DLT: Dose-limiting toxicities.

Citation: Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472
URL: https://www.wjgnet.com/2218-4333/full/v13/i6/448.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i6.448